-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On November 16, Wu Zhong Medicine issued an announcement stating that the company had received the "Drug Supplementary Application Approval Notice" for "Lansoprazole for Injection" and "Mesopalmol Injection" approved and issued by the State Food and Drug Administration.
1.
1.
The company's lansoprazole consistency evaluation project for injection was established in 2018, and a supplementary application for the consistency evaluation of lansoprazole for injection was submitted in March 2020, and the drug supplement application approval was recently obtained
2.
2.
The company's methobacmol injection consistency evaluation project was established in 2018, and a supplementary application for the consistency evaluation of methobacmol injection was submitted in April 2020, and the drug supplement application approval was recently obtained
After inquiries, the domestic sample hospital sales of methocarbamol injection in 2020 are about 41,774,300 yuan (PDB database)
According to relevant national policies and regulations, appropriate support should be given to medical insurance payment for drug varieties that have passed the consistency evaluation of generic drugs, and medical institutions should give priority to procurement and give priority to selection in clinical practice
